4D pharma’s Blautix has met its primary endpoint in the Phase II irritable bowel syndrome (IBS) trial of improving overall response rate (ORR) in IBS patients with either IBS-Constipation and IBS-Diarrhoea vs. placebo, although we note a lower level of significance (0.1) was used. Whilst this presents a statistical concern, the results do enough to show a efficacy signal in IBS and the observed ORR effect size demonstrated by Blautix vs. placebo is numerically comparable to other drugs ....